Breaking News Instant updates and real-time market news.

A

Agilent

$60.20

0.26 (0.43%)

, ABT

Abbott

$49.23

0.08 (0.16%)

04:55
08/03/17
08/03
04:55
08/03/17
04:55

American Association for Clinical Chemistry holds a meeting

69th AACC Annual Scientific Meeting 2017 is being held in San Diego, CA on July 30-August 3.

A

Agilent

$60.20

0.26 (0.43%)

ABT

Abbott

$49.23

0.08 (0.16%)

BIO

Bio-Rad

$238.60

0.89 (0.37%)

CEMI

Chembio Diagnostics

$6.45

-0.1 (-1.53%)

CGNX

Cognex

$101.61

-3.67 (-3.49%)

DGX

Quest Diagnostics

$107.97

-0.37 (-0.34%)

DX

Dynex Capital

$7.20

0.28 (4.05%)

GLW

Corning

$29.77

0.25 (0.85%)

GNMK

GenMark

$10.87

0.165 (1.54%)

HAE

Haemonetics

$40.38

-0.64 (-1.56%)

LMNX

Luminex

$20.20

-0.02 (-0.10%)

MCK

McKesson

$159.61

-1.65 (-1.02%)

OSUR

OraSure

$17.27

-0.48 (-2.70%)

PKI

PerkinElmer

$66.72

0.5 (0.76%)

QDEL

Quidel

$31.74

-0.19 (-0.60%)

SIEGY

Siemens

$68.87

0.11 (0.16%)

SRDX

Surmodics

$25.70

-0.15 (-0.58%)

TECH

Bio-Techne

$115.42

-0.36 (-0.31%)

THC

Tenet

$16.80

-0.52 (-3.00%)

TMO

Thermo Fisher

$176.44

0.97 (0.55%)

WAT

Waters

$176.69

0.95 (0.54%)

ZBRA

Zebra Technologies

$97.75

-3.4 (-3.36%)

  • 03

    Aug

  • 03

    Aug

  • 03

    Aug

  • 06

    Aug

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 09

    Aug

  • 10

    Aug

  • 10

    Aug

  • 15

    Aug

  • 16

    Aug

  • 17

    Aug

  • 21

    Sep

  • 22

    Sep

A Agilent
$60.20

0.26 (0.43%)

06/07/17
06/07/17
DOWNGRADE
Target $95

Neutral
Danaher downgraded to Neutral on relative growth potential at Janney Capital
As previously reported, Janney Capital analyst Paul Knight downgraded Danaher (DHR) to Neutral from Buy, stating that he sees the company having more work to do optimizing its portfolio. He believe peers such as Waters (WAT) and Agilent (A) are more likely to see upward growth revisions compared to Danaher, where he feels a meaningful acceleration in organic growth is already priced in. He keeps a $95 fair value estimate on Danaher shares.
07/12/17
WELS
07/12/17
UPGRADE
WELS
Outperform
Agilent upgraded to Outperform from Market Perform at Wells Fargo
07/13/17
WELS
07/13/17
NO CHANGE
WELS
Wells Fargo adjusts ratings in Life Science Tools space
Wells Fargo analyst Tim Evans changed ratings in the Life Science Tools sector to reflect in order to prioritize the pharma end market. For a Tools company, the pharma end market is "less price sensitive, less competitive, and more receptive to product cycles," Evans tells investors in a research note. To reflect this thesis, the analyst upgraded both Mettler-Toledo (MTD) and Agilent (A) to Outperform from Market Perform. He raised his price target for Mettler to $660 from $510 and for Agilent to $67 from $60. The analyst also downgraded Bruker (BRKR) to Underperform from Market Perform with an unchanged price target of $25. His favorite name in the Life Science Tools portion of his universe is Waters (WAT).
07/13/17
07/13/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying Snap shares offer a "compelling risk/reward opportunity." 2. Progressive (PGR) upgraded to Strong Buy from Outperform at Raymond James with analyst Gregory Peters saying he believes Progressive will continue to grow net premiums written at a double digit pace through 2017 and is well positioned to benefit from emerging smartphone technology to monitor and price for distracting driving over the next 24 months. 3. Agilent (A) upgraded to Outperform from Market Perform at Wells Fargo. 4. Hain Celestial (HAIN) upgraded to Buy from Hold at Maxim with analyst Anthony Vendetti saying that its fiscal 2018 guidance implies a turnaround in its business while the company's reporting of its prior financials without any major restatements has removed an accounting overhang. 5. Fastenal (FAST) upgraded to Strong Buy from Outperform at Raymond James analyst Sam Darkatsh saying he thinks yesterday's selloff in Fastenal shares is entirely related to MSC Industrial's (MSM) gross margin commentary and is unwarranted. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABT Abbott
$49.23

0.08 (0.16%)

07/14/17
COWN
07/14/17
NO CHANGE
Target $55
COWN
Outperform
Abbott likely biggest beneficiary of CMS changes for MRI coverages, says Cowen
Cowen analyst Joshua Jennings said he believes the CMS will consider covering MRI for patients with CRM devices that do not have FDA-approved MR-safe labeling. Jennings believes this should neutralize any unanticipated fallout from Abbott's Sylmar facility warning letter if it removes the need to secure MR-safe labeling. The analyst, who said he hopes to gain insight into the MRI considerations over the next month, maintained his Outperform rating and $55 price target on Abbott shares.
07/13/17
BTIG
07/13/17
NO CHANGE
BTIG
Buy
Abbott, Bigfoot deal a 'major validation' for both, says BTIG
BTIG analyst Sean Lavin sees Abbott's (ABT) deal to collaborate with Bigfoot Biomedical as a major validation of both Abbott's Libre technology and the platform of Bigfoot, which he views as a leader in the development of automated pancreases. For Dexcom (DXCM), this is a missed opportunity that could also be a sign that its grip on the CGM market may fade over time, but the company still has multiple shots with other pump systems and remains the market leader of standalone CGM, said Lavin. Insulet (PODD) is well underway in developing its Horizon AP platform and is unlikely to switch from Dexcom for its CGM, added Lavin, who keeps a Buy rating on Abbott and a Neutral rating on Dexcom.
07/13/17
ADAM
07/13/17
NO CHANGE
Target $90
ADAM
Buy
Dexcom loss of Bigfoot as partner will be viewed negatively, says Canaccord
Canaccord analyst Kyle Rose said it is "hard not to view today's news" of a partnership with Bigfoot Biomedical as a big win for Abbott (ABT) and a disappointing loss for incumbent partner Dexcom (DXCM). While the loss of Bigfoot is unlikely to fundamentally impact Dexcom over the near term, Rose thinks investors will view it negatively since this news eliminates a potentially key pump partner for Dexcom and give's Abbott's Libre strategy a "strong backing," he tells investors. The analyst has a Buy rating and $90 price target on Dexcom shares.
07/13/17
JEFF
07/13/17
NO CHANGE
Target $58
JEFF
Buy
Bigfoot selected Abbott over Dexcom, says Jefferies
Jefferies analyst Raj Denhoy says that in a surprise move, Bigfoot Biomedical selected Abbott's (ABT) FreeStyle Libre as the continuous glucose monitor for its diabetes management system over Dexcom (DXCM) and others. The selection of Abbott is an endorsement of the company's "simplicity over point accuracy," the analyst contends. Shares of Dexcom (DXCM) are down 3% to $69.92 in early trading.
BIO Bio-Rad
$238.60

0.89 (0.37%)

07/13/17
WELS
07/13/17
INITIATION
Target $250
WELS
Outperform
Bio-Rad initiated with an Outperform at Wells Fargo
Wells Fargo analyst Tim Evans started Bio-Rad Laboratories with an Outperform rating and $250 price target. The company offers an "interesting way to get exposure to the attractive bioproduction market," the analyst contends.
06/28/17
DBAB
06/28/17
UPGRADE
Target $255
DBAB
Buy
Bio-Rad upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Dan Leonard upgraded Bio-Rad Laboratories to Buy saying the company's sales growth and margin expansion should accelerate following a multi-year investment period. He expects the company to generate industry-leading earnings growth and upped his price target for the shares to $255 from $220.
03/14/17
JEFF
03/14/17
NO CHANGE
Target $250
JEFF
Buy
Bio-Rad path to $300 per share 'a lot clearer,' says Jefferies
Jefferies analyst Brandon Couillard believes yesterday's updates from Bio-Rad Laboratories, which included 2020 revenue and margin goals, a capital allocation plan which opens the door to buybacks as well as board changes, make the path to $300 per share over the next few years "a lot clearer." It is time to forget everything you thought you knew about Bio-Rad, Couillard tells investors in a research note. He raised his price target for the stock to $250 from $225 and keeps a Buy rating on the name.
01/18/17
DBAB
01/18/17
INITIATION
Target $195
DBAB
Hold
Bio-Rad initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Dan Leonard started Bio-Rad with a Hold rating and $195 price target.
CEMI Chembio Diagnostics
$6.45

-0.1 (-1.53%)

CGNX Cognex
$101.61

-3.67 (-3.49%)

08/02/17
COWN
08/02/17
NO CHANGE
Target $135
COWN
Outperform
Cognex price target raised to $135 from $100 at Cowen
05/02/17
COWN
05/02/17
NO CHANGE
Target $100
COWN
Outperform
Cognex guidance stronger than numbers suggest, says Cowen
Cowen analyst Joseph Giordano said Cognex Q1 results beat the high end of guidance and Q2 should beat as well. He said any weakness on confusion about the headline guidance should be bought aggressively and he reiterated Cognex as a top pick. Giordano has an Outperform rating and raised his price target to $100 from $90 on Cognex shares.
04/07/17
BERN
04/07/17
NO CHANGE
BERN
Cognex acquisition positive, says Bernstein
After Cognex agreed to buy ViDi Systems SA, Bernstein analyst Jay Huang says the deal "makes perfect strategic sense." He says that ViDi addresses the need for deep learning in industrial inspection and can improve the functioning of Cognex products while expanding the areas in which they can be used. Huang adds that the deal should play an important role in helping Cognex maintain its leadership in the vision industry over the long run. However, he keeps a Market Perform rating on the stock.
04/03/17
GSCO
04/03/17
INITIATION
Target $95
GSCO
Buy
Cognex initiated with a Buy at Goldman
Goldman Sachs analyst Joseph Ritchie started Cognex with a Buy rating and $95 price target.
DGX Quest Diagnostics
$107.97

-0.37 (-0.34%)

07/25/17
PIPR
07/25/17
NO CHANGE
Target $107
PIPR
Neutral
Quest Diagnostics price target raised to $107 from $93 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Quest Diagnostics to $107 following the company's Q2 results. While Quest's fundamentals "are as strong as they have been in years," there is risk of longer-term multiple convergence with peer LabCorp (LH), Quirk tells investors in a research note. He keeps a Neutral rating on the shares.
07/25/17
BOFA
07/25/17
UPGRADE
BOFA
Buy
Quest Diagnostics upgraded to Buy from Neutral at BofA/Merrill
07/25/17
BOFA
07/25/17
UPGRADE
Target $118
BOFA
Buy
Quest Diagnostics upgraded on view FY18 consensus too low at BofA/Merrill
As previously reported, BofA/Merrill Lynch analyst Steven Valiquette upgraded Quest Diagnostics to Buy from Neutral as he believes that consensus estimates for 2018 seem too low given Quest's current momentum and the company's increased FY17 sales and EPS guidance. Valiquette raised his 2018 EPS estimate to $6.08, which he noted is "well above" the current consensus view of $5.91, adding that a delay in PAMA reimbursement changes could yield further EPS upside. The analyst increased his price target on Quest shares to $118 from $111.
07/26/17
ADAM
07/26/17
NO CHANGE
Target $118
ADAM
Buy
Quest Diagnostics weakness overdone, says Canaccord
Canaccord analyst Mark Massaro said Quest Diagnostics delivered solid Q2 results and raised its guidance. He believes Quest is well positioned to achieve growth from acquisitions, develop higher fee cash flow, and continue stock buybacks. Massaro said yesterday's modest pullback is overdone and he reiterated his Buy rating and $118 price target on Quest Diagnostics shares.
DX Dynex Capital
$7.20

0.28 (4.05%)

01/13/17
JMPS
01/13/17
DOWNGRADE
JMPS
Market Perform
Dynex Capital downgraded based on valuation at JMP Securities
As noted earlier, JMP Securities downgraded Dynex Capital to Market Perform from Outperform. Analyst Trevor Cranston downgraded the stock based on valuation.
01/13/17
JMPS
01/13/17
DOWNGRADE
JMPS
Market Perform
Dynex Capital downgraded to Market Perform from Outperform at JMP Securities
GLW Corning
$29.77

0.25 (0.85%)

04/19/17
STFL
04/19/17
NO CHANGE
STFL
Dycom could obtain $300M in revenue from Verizon, says Stifel
After Verizon (VZ) announced a three year agreement to purchase fiber from Corning (GLW), Stifel analyst Noelle Dilts says that Verizon's upcoming deployment of fiber could generate $300M of additional annual revenue for Dycom (DY). The analyst estimates that Verizon's deployment could add 64c to Dycom's annual EPS. She raised her price target on the shares to $120 from $112 and keeps a Buy rating on the stock.
04/19/17
ARGS
04/19/17
NO CHANGE
ARGS
Corning price target raised to $33 from $30 at Argus
Argus analyst Jim Kelleher increased his price target on Corning (GLW) after the company announced a $1.05B fiber supply deal with Verizon (VZ). The analyst says that Corning's valuation is attractive and keeps a Buy rating on the shares.
04/19/17
04/19/17
NO CHANGE

Zayo Group has negative read through from Verizon deal, says Pacific Crest
After Verizon (VZ) agreed to buy fiber from Corning (GLW), Pacific Crest analyst Brandon Nispel says the deal indicates that Verizon prefers to build a fiber network on its own instead of leasing one from a third party. The analyst views this development as negative for Zayo which is building and looking to lease fiber networks. He keeps a Sector Weight rating on the stock.
04/26/17
UBSW
04/26/17
NO CHANGE
Target $29
UBSW
Neutral
Corning doing better than expected, says UBS
UBS analyst Tejas Venkatesh noted Corning (GLW) beat expectations for Q1 and its guidance surpassed expectations, leading him to say the company is doing better than expected. He also believes the company's deal with Verizon (VZ) is significant, though he maintains his Neutral rating on Corning shares due to currency risk that keeps him on the sidelines. Venkatesh raised his price target to $28.50 from $26 on Corning.
GNMK GenMark
$10.87

0.165 (1.54%)

08/02/17
ADAM
08/02/17
NO CHANGE
Target $17
ADAM
Buy
GenMark weakness looks 'moderately irrational,' says Canaccord
Canaccord analyst Mark Massaro noted GenMark announced in-line Q2 results and reiterated its 2017 guidance. He characterized the ensuing selloff as "moderately irrational" given there was no change to his thesis. The analyst believes the company is well positioned to penetrate its market and scale it new platform with its strong sales team. Massaro reiterated his Buy rating and $17 price target on GenMark shares.
08/01/17
COWN
08/01/17
NO CHANGE
COWN
Outperform
GenMark outlook 'largely intact,' pullback a buying opportunity, says Cowen
Cowen analyst Doug Schenkel attributes Genmark's post-earnings pullback to details on revenue mix, orders, and margins that appear to have heightened some uncertainty on its outlook. However, he thinks additional details on its ePlex placement and order trends are encouraging and believes the company's revenue and gross margin outlook are "largely intact," making today's weakness a buying opportunity. Schenkel keeps an Outperform rating on Genmark, which is down about 13% near midday.
05/03/17
ADAM
05/03/17
NO CHANGE
Target $17
ADAM
Buy
GenMark appears on cusp of big U.S. launch, says Canaccord
Canaccord analyst Mark Massaro noted GenMark delivered another good quarter and, more importantly, expects FDA approval on the ePlex system and the Respiratory Panel very soon. The analyst believes the company may be a few weeks away from the approval and a strong commercial launch. Massaro raised his estimates and reiterated his Buy rating while raising his price target to $17 from $14 on GenMark shares.
02/07/17
COWN
02/07/17
NO CHANGE
Target $17
COWN
Outperform
GenMark concern surrounding NeoPrep discontinuation overblown, says Cowen
Cowen analyst Doug Schenkel noted GenMark (GNMK) shares have declined 10% year-to-date, which he attributes to concerns surrounding Illumina's (ILMN) decision to discontinue NeoPrep. The analyst believes these concerns are overblown as the company has entered into an amended supply agreement, which was confirmed in their 10-Q. Schenkel maintained his Outperform rating and $17 price target on GenMark shares.
HAE Haemonetics
$40.38

-0.64 (-1.56%)

07/13/17
JMPS
07/13/17
UPGRADE
JMPS
Outperform
Haemonetics upgraded on increased confidence in turnaround at JMP Securities
As noted earlier, JMP Securities upgraded Haemonetics to Outperform from Market Perform. Analyst David Turkaly says he has increased confidence in the company's turnaround based on its new management and new strategy. Target $50.
07/13/17
JMPS
07/13/17
UPGRADE
JMPS
Outperform
Haemonetics upgraded to Outperform from Market Perform at JMP Securities
02/07/17
02/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Restoration Hardware (RH) downgraded to Underperform from Neutral at Buckingham with the firm's analyst recommending using Restoration Hardware shares as a source of funds ahead of fourth quarter earnings March 30 as he expects a choppy road to recovery in fiscal 2017, marked by trade offs between revenus and margins. Further, Buckingham said liquidity issues could loom large in investors minds this year with its first tranche of $350M in convertible debt due in June 2019, combined with execution challenges, creates uncertainty around a potential earnings recovery. 2. Capstead Mortgage (CMO) downgraded to Market Perform from Outperform at Wells Fargo with analyst Joel Houck saying a modest dividend reduction in the near term can't be ruled out following the company's "disappointing" Q4 results. 3. Asanko Gold (AKG) downgraded to Hold from Speculative Buy at Canaccord with analyst Rahul Paul citing an update on its Asanko Gold mine expansion. The company indicated that mineral reserve is not expected to materially change, and as a result, the analyst lowered his expected reserve additions. 4. Haemonetics (HAE) downgraded to Market Perform from Outperform at Barrington with analyst Michael Petusky citing reduced expectations for next year following the company's third quarter results. The analyst thinks the shares are about fairly valued. 5. Herc Rentals (HRI) downgraded to Neutral from Buy at Northcoast with analyst John Healy saying shares have exceeded his price target of $48 and views risk/reward as balanced. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/07/17
BRRR
02/07/17
DOWNGRADE
BRRR
Market Perform
Haemonetics downgraded to Market Perform from Outperform at Barrington
Barrington analyst Michael Petusky downgraded Haemonetics to Market Perform citing reduced expectations for next year following the company's Q3 results. The analyst thinks the shares are about fairly valued.
LMNX Luminex
$20.20

-0.02 (-0.10%)

08/18/16
JPMS
08/18/16
UPGRADE
Target $22
JPMS
Neutral
Luminex upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Tycho Peterson upgraded Luminex to Neutral saying operational improvements and strong performance of the company's core business make the short thesis less compelling. The analyst raised his price target for the shares to $22 from $18.
10/12/16
AVON
10/12/16
INITIATION
Target $27
AVON
Outperform
Luminex initiated with an Outperform at Avondale
Avondale analyst Sung Ji Nam initiated Luminex with an Outperform and a $27 price target.
10/12/16
10/12/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AB InBev (BUD) reinstated with an Outperform at Credit Suisse. 2. GrubHub (GRUB) initiated with a Buy at Argus. 3. Dave & Buster's (PLAY) initiated with an Outperform at Wells Fargo. 4. Buckeye Partners (BPL) initiated with a Neutral at Credit Suisse. 5. Luminex (LMNX) initiated with an Outperform at Avondale. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/18/17
DBAB
01/18/17
INITIATION
Target $18
DBAB
Sell
Luminex initiated with a Sell at Deutsche Bank
Deutsche Bank analyst Dan Leonard started Luminex (LMNX) with a Sell rating and $18 price target, as he believes the anticipated revenue losses from LabCorp (LH) will be difficult to offset, leading to revenue stagnation over the next few years.
MCK McKesson
$159.61

-1.65 (-1.02%)

05/23/17
JPMS
05/23/17
UPGRADE
Target $189
JPMS
Overweight
McKesson upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Lisa Gill upgraded McKesson to Overweight and raised her price target for the shares to $189 from $167. The analyst believes additional value should be unlocked from the Change transaction and that the valuation discount versus peers is unwarranted.
05/23/17
05/23/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McKesson (MCK) upgraded to Overweight from Neutral at JPMorgan with analyst Lisa Gill saying she believes additional value should be unlocked from the Change transaction and that the valuation discount versus peers is unwarranted. 2. Aegion (AEGN) upgraded to Buy from Hold at Craig-Hallum with analyst Eric Stine saying the recent pullback provides an attractive opportunity to own a "high-quality company" with positive trends across much of its business. 3. Wingstop (WING) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Karen Holthouse saying there is upside to her $36 price target. Holthouse believes Wingstop is well positioned for digital ordering and off-premise tailwinds and expects an acceleration in same-store-sales driven by national advertising momentum. 4. Parexel (PRXL) upgraded to Neutral from Sell at Goldman Sachs with analyst Robert Jones citing reduced consensus expectations and industry consolidation. 5. On Deck Capital (ONDK) upgraded to Outperform from Market Perform at FBR Capital with analyst Bob Ramsey saying he believes the company's path to profitability creates "significant" upside for the shares over the next 12 months. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/17
MSCO
05/24/17
NO CHANGE
Target $179
MSCO
Overweight
McKesson price target raised to $179 on earnings acceleration at Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser raised McKesson's price target to $179 from $164 saying 2018 guidance sets a path for earnings acceleration over the next 18 months supported by improved sourcing, easing comps, and acquisitions. Shares of McKesson are Overweight rated.
06/29/17
LEER
06/29/17
NO CHANGE
Target $170
LEER
Market Perform
McKesson price target raised to $170 from $140 at Leerink
Leerink analyst David Larsen raised his price target for McKesson to $170 following the company's analyst day. The depth of the company's specialty solutions and expansion activities impressed us, but no new long-term operating earnings goals were provided, Larsen tells investors in a research note. The analyst remains skeptical on McKesson's ability to get back to double digit earnings growth in the near-term and keeps a Market Perform rating on the shares.
OSUR OraSure
$17.27

-0.48 (-2.70%)

06/28/17
JEFF
06/28/17
NO CHANGE
Target $19
JEFF
Buy
OraSure deal with Gates Foundation a 'major positive,' says Jefferies
Jefferies analyst Brandon Couillard raised his price target for OraSure to $19 saying the Gates Foundation deal will facilitate accelerated adoption of the company's HIV self-test in emerging markets while ensuring favorable economics and margins. The analyst views the deal as a "major positive" that removes uncertainty around how quickly OraSure's HIV test can ramp. He keeps a Buy rating on the shares.
06/27/17
JEFF
06/27/17
NO CHANGE
Target $19
JEFF
Buy
OraSure price target raised to $19 from $16 at Jefferies
06/27/17
ADAM
06/27/17
NO CHANGE
Target $18
ADAM
Buy
OraSure price target raised to $18 from $15 at Canaccord
Canaccord analyst Mark Massaro said OraSure's agreement with the Bill & Melinda Gates Foundation will effectively subsidize the cost of the company's HIV self test, which can add millions of revenue beginning in 2018, with some partial lift in 2017. The analyst, who views OraSure as having " multiple shots on goal" in addition to the HIV test, keeps a Buy rating on the stock and raised his price target to $18 from $15.
04/06/17
RAJA
04/06/17
NO CHANGE
RAJA
Outperform
Raymond James says 23andMe FDA approval bodes well OraSure
Raymond James analyst Nicholas Jansen said the FDA announced it would allow 23andMe to market Genetic Health Risk, or GHR tests for 10 diseases or conditions. OraSure is the provider of the collections device through its subsidiary DNA Genotek, and the analyst views this new development to be a clear positive. Jansen said the approval will reaccelerate the growth rate ahead of growing consumer awareness and reiterates his Outperform rating OraSure shares.
PKI PerkinElmer
$66.72

0.5 (0.76%)

07/13/17
WELS
07/13/17
INITIATION
Target $72
WELS
Market Perform
PerkinElmer initiated with a Market Perform at Wells Fargo
Wells Fargo analyst Tim Evans started PerkinElmer with a Market Perform rating and $72 price target.
07/13/17
WELS
07/13/17
INITIATION
WELS
Market Perform
PerkinElmer initiated at Wells Fargo
As noted earlier, Wells Fargo analyst Tim Evans started coverage of PerkinElmer with a $72 price target and a Market Perform rating. The analyst says that the company's operating results have improved over the past few years, but its "track record on capital deployment, deal execution, and long-term targets has been mixed."
07/25/17
PIPR
07/25/17
NO CHANGE
Target $80
PIPR
Overweight
PerkinElmer price target raised to $80 from $63 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for PerkinElmer shares to $80 to reflect the acquisition of Euroimmun. The potential for re-accelerating top and bottom-line growth should keep shares "inching higher," Quirk tells investors in a research note. He recommends using any weakness related to declining U.S. birth rates, which he notes could weigh on the company's domestic newborn screening business in the short to mid-term, as a buying opportunity. The analyst keeps an Overweight rating on PerkinElmer.
07/28/17
DBAB
07/28/17
NO CHANGE
Target $175
DBAB
Hold
Deutsche uncovers 'surprise' Illumina order from PerkinElmer
Deutsche Bank analyst Dan Leonard says he learned at a recent genetics conference that PerkinElmer (PKI) placed a "surprise" order with Illumina (ILMN) for 10 NovaSeq's to support its planned offering in clinical nextgen sequencing. The analyst finds the size of the order, not PerkinElmer being a customer, as a surprise. Ten NovaSeq's is equivalent to the order placed by the Broad Institute, one of the largest genome centers in the world, the analyst points out. He believes demand for newborn sequencing is growing rapidly, "albeit off a small base." The order challenges, but does not change, the analyst's view that the NovaSeq product cycle is not as rapid as HiSeq's. Leonard keeps a Hold rating on Illumina shares with a $175 price target. The stock in early trading is up 44c to $174.77.
QDEL Quidel
$31.74

-0.19 (-0.60%)

07/18/17
WBLR
07/18/17
UPGRADE
WBLR
Outperform
Quidel upgraded to Outperform from Market Perform at William Blair
William Blair analyst Brian Weinstein upgraded Quidel to Outperform following the company's acquisition of Alere's Triage assets. Canaccord Genuity this morning also upgraded the shares.
07/18/17
ADAM
07/18/17
UPGRADE
Target $42
ADAM
Buy
Quidel upgraded to Buy from Hold at Canaccord
Canaccord analyst Mark Massaro upgraded Quidel (QDEL) to Buy from Hold as it is a beneficial buyer of Alere (ALR) assets. The analyst said the deal doubles the company's revenues, is immediately accretive, was bought at a low multiple to market value, and provides the company with new platforms to add tests on. Massaro raised his price target to $42 from $25 on Quidel shares.
02/17/17
KING
02/17/17
INITIATION
KING
Neutral
Quidel initiated with a Neutral at CL King
12/16/16
PIPR
12/16/16
DOWNGRADE
Target $22
PIPR
Neutral
Quidel downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst William Quirk downgraded Quidel to Neutral saying the current Street estimates largely include a stronger flu season. He sees limited upside from a "flu trade" and keeps a $22 price target for the shares.
SIEGY Siemens
$68.87

0.11 (0.16%)

09/07/16
UBSW
09/07/16
DOWNGRADE
UBSW
Neutral
Siemens downgraded to Neutral from Buy at UBS
UBS downgraded Siemens to Neutral saying the risk/reward is not attractive enough at current valuation levels.
01/10/17
UBSW
01/10/17
UPGRADE
UBSW
Buy
Siemens upgraded to Buy from Neutral at UBS
01/11/17
GSCO
01/11/17
DOWNGRADE
GSCO
Sell
Siemens downgraded to Sell from Buy at Goldman
Goldman Sachs analyst Daniela Costa double downgraded Siemens to Sell from Buy and lowered her price target for the shares to EUR 100 from EUR 118.
SRDX Surmodics
$25.70

-0.15 (-0.58%)

07/14/17
LSCM
07/14/17
INITIATION
Target $40
LSCM
Buy
Surmodics initiated with a Buy at Lake Street
Lake Street analyst Brooks O'Neil started Surmodics with a Buy rating and $40 price target. Positive news flow from the company's new product offerings should be a catalyst over the next few quarters, the analyst contends.
06/27/17
AGIS
06/27/17
INITIATION
Target $43.5
AGIS
Buy
SurModics initiated with a Buy at Aegis
Aegis analyst Benjamin Haynor initiated Surmodics with a Buy and a $43.50 price target saying the current pipeline has a dozen products seeking FDA 510 clearances as well as a third-generation drug-coated balloon platform which will require a PMA approval. He expects SurModics to seek partnering for each device and does not believe earnings power is appreciated by investors.
11/21/16
11/21/16
DOWNGRADE

Market Perform
SurModics downgraded to Market Perform at Barrington
As previously reported, Barrington analyst Michael Petusky downgraded SurModics to Market Perform from Outperform after the company's guidance for FY17 was meaningfully below consensus and his expectations. The analyst, who said he continues to like "much of what he sees" at SurModics, said he would revisit his rating if shares weaken "materially" from current levels.
11/21/16
BRRR
11/21/16
DOWNGRADE
BRRR
Market Perform
SurModics downgraded to Market Perform from Outperform at Barrington
TECH Bio-Techne
$115.42

-0.36 (-0.31%)

07/13/17
WELS
07/13/17
INITIATION
Target $110
WELS
Market Perform
Bio-Techne initiated with a Market Perform at Wells Fargo
Wells Fargo analyst Tim Evans started Bio-Techne with a Market Perform rating and $110 price target. The analyst believes high expectations are priced into the stock.
03/27/17
JANY
03/27/17
DOWNGRADE
JANY
Neutral
Bio-Techne downgraded to Neutral from Buy at Janney Capital
02/09/17
02/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ulta Beauty (ULTA) initiated with a Hold at Loop Capital. 2. Spark Therapeutics (ONCE) initiated with an Outperform at Leerink. 3. GTT Communications (GTT) initiated with a Buy at BTIG. 4. Westlake Chemical (WLK) initiated with a Buy at Citi. 5. Bio-Techne (TECH) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/09/17
SBSH
02/09/17
INITIATION
Target $115
SBSH
Buy
Bio-Techne initiated with a Buy at Citi
Citi analyst Daniel Arias started Bio-Techne with a Buy rating and $115 price target. The analyst likes the company's accelerating organic growth and views the company as a good takeover candidate.
THC Tenet
$16.80

-0.52 (-3.00%)

06/06/17
LEER
06/06/17
UPGRADE
LEER
Outperform
Tenet upgraded to Outperform from Market Perform at Leerink
06/07/17
LEER
06/07/17
UPGRADE
LEER
Outperform
Leerink upgrades hospitals HCA, LifePoint, Tenet to Outperform
Leerink analyst Ana Gupte last night upgraded hospitals HCA Holdings (HCA), LifePoint (LPNT) and Tenet healthcare (THC) to Outperform from Market Perform. She raised her price target for HCA to $100 from $90, for LifePoint to $74 from $73 and maintains a $27 price target for HCA. The targets offer upside of 21%, 20% and 62% respectively. Anthem's (ANTM) announced exit yesterday from the key swing state of Ohio's healthcare exchange could bring further attention to the need for stabilization funding through legislation, Gupte tells investors in a research note. She believes improving policy under the Trump Administration could drive upside to 2018 and 2019 consensus estimates. Further, the analyst thinks medium term downside risk from Republican's repeal and replace healthcare bill is likely better than feared as publicly traded hospitals are "heavily weighted to non-expansion states," which lessons the impact of Medicaid expansion funding cuts.
06/07/17
06/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ormat Technologies (ORA) upgraded to Overweight from Neutral at JPMorgan with analyst Paul Coster saying he believes the company is well positioned to continue posting revenue growth and margin expansion over the next few years. 2. Tenet (THC) upgraded to Outperform from Market Perform at Leerink. 3. Cott Corp. (COT) and Dr Pepper Snapple (DPS) were upgraded to Outperform from Market Perform at BMO Capital. 4. Sun Life Financial (SLF) upgraded to Outperform from Sector Perform at RBC Capital with analyst Darko Mihelic saying net flows and Assets Under Management at the company's MFS unit have improved over the last two months. He also notes that the stock has fallen about 12% since February. 5. Valvoline (VVV) upgraded to Buy from Neutral at Seaport Global with analyst Michael Harrison saying he expects the oil market to return to looser supply/demand and pricing to decline in the summer once Motiva completes its Port Arthur, TX turnaround in June, which would be a positive for Valvoline margins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
TMO Thermo Fisher
$176.44

0.97 (0.55%)

07/26/17
WELS
07/26/17
NO CHANGE
Target $200
WELS
Outperform
Thermo Fisher weakness a buying opportunity, says Wells Fargo
Wells Fargo analyst Tim Evans would use weakness in Thermo Fisher shares as a buying opportunity saying his long-term positive view of the pharma market is unchanged, but investor expectations may be a bit too high. Evans said Thermo has more flexibility on capital deployment than peers, giving it advantages when it comes to acquisitions or share repurchases. Shares are Outperform rated with a $200 price target.
07/20/17
CLVD
07/20/17
UPGRADE
CLVD
Buy
Thermo Fisher upgraded to Buy on strong trends at Cleveland Research
As previously reported, Cleveland Research upgraded Thermo Fisher to Buy from Neutral with a $206 price target. Analyst Steve Willoughby said checks indicate Pharma customer demand remains strong while Industrial and Academic demand appears to be improving. As a result, the analyst now sees upside to management's guidance of 4% organic growth guidance in 2017 and sees further upside in shares from improving fundamentals.
07/20/17
CLVD
07/20/17
UPGRADE
CLVD
Buy
Thermo Fisher upgraded to Buy from Neutral at Cleveland Research
06/09/17
DBAB
06/09/17
NO CHANGE
Target $200
DBAB
Buy
Thermo Fisher price target raised to $200 from $188 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Thermo Fisher (TMO) to $200 following his deeper look at the proposed Patheon (PTHN) acquisition. Cross-selling opportunities between the two companies do exist, but are difficult to quantify, Leonard tells investors in a research note. He keeps a Buy rating on Thermo shares.
WAT Waters
$176.69

0.95 (0.54%)

07/10/17
DBAB
07/10/17
DOWNGRADE
Target $194
DBAB
Hold
Waters downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Dan Leonard downgraded Waters to Hold citing valuation with the shares up 37% year-to-date. The analyst also sees less room for margin expansion relative to peers. He raised his price target for the shares to $194 from $183.
07/10/17
07/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Underperform from Hold at Jefferies with analyst Mark Lipacis saying the chipmaker's Xeon/Xeon PHI platform is disadvantaged versus Nvidia (NVDA) in emerging parallel workloads like deep neural networking. 2. Five Below (FIVE) downgraded to Neutral from Buy at UBS with analyst Michael Lasser saying he expects the shares to be range-bound in the near-term as the company manages through the "fading of the fidget spinner trend." 3. Waters (WAT) downgraded to Hold from Buy at Deutsche Bank with analyst Dan Leonard citing valuation with the shares up 37% year-to-date. 4. Costco (COST) downgraded to Market Perform from Outperform at BMO Capital. 5. Dick's Sporting (DKS) downgraded to Neutral from Buy at Cleveland Research with analyst Daryl Boehringer citing industry headwinds, particularly in apparel, which leaves him more cautious on second quarter comparables and margins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/20/17
CLVD
07/20/17
NO CHANGE
CLVD
Buy
Cleveland Research expects upside to Waters Q2 and 2017
Cleveland Research analyst Steve Willoughby said his research indicates strong end market demand in Pharma & Industrial likely continued in Q2 and Academic customers may be showing signs of improvement. He expects Water's Q2 revenue of $571M, versus consensus of $553M, and raised his earnings estimate to $1.76, versus consensus of $1.71. Willoughby rates Waters a Buy with a $195 price taret.
ZBRA Zebra Technologies
$97.75

-3.4 (-3.36%)

05/10/17
WELS
05/10/17
DOWNGRADE
Target $105
WELS
Market Perform
Zebra Technologies downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Andrew Spinola downgraded Zebra Technologies to Market Perform citing valuation following the company's "solid" Q1 results. The analyst has a $105 price target for the shares.
05/31/17
MSCO
05/31/17
DOWNGRADE
MSCO
Equal Weight
Zebra Technologies downgraded to Equal Weight from Overweight at Morgan Stanley
05/31/17
MSCO
05/31/17
DOWNGRADE
Target $100
MSCO
Equal Weight
Zebra Technologies downgraded to Equal Weight on valuation at Morgan Stanley
As previously reported, Morgan Stanley downgraded Zebra Technologies to Equal Weight and raised its price target to $100 from $95. Analyst James Faucette said valuation is now appropriate given growth trends and debt load, which are now reflected in 2018 expectations.
05/31/17
05/31/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Koppers Holdings (KOP) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander saying shares will remain range-bound, "at best," amid "depressed" railroad spending. End market growth is unlikely to return until 2020-2021, Alexander tells investors. He lowered his price target for the shares to $40 from $48. 2. iRobot (IRBT) downgraded to Hold on valuation at Canaccord with analyst Bobby Burleson citing the 70% share appreciation year-to-date. He maintained a $90 price target saying he expects only modest upside to estimate for the rest of the year. 3. Molina Healthcare (MOH) downgraded to Sell from Hold at Stifel with analyst Thomas Carroll citing valuation and his belief that the company will have difficulty meeting the Street's expectations on margins, while investors are underestimating the risk to the company's revenues and overestimating the chances of the company selling itself in the near-term. 4. ING Group (ING) downgraded to Hold from Buy at HSBC with analyst Robin Down saying the stock is near fair value after rallying 17% over the past three months. 5. Zebra Technologies (ZBRA) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst James Faucette saying valuation is now appropriate given growth trends and debt load, which are now reflected in 2018 expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

DE

Deere

$139.23

2.31 (1.69%)

20:25
11/21/17
11/21
20:25
11/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 28

    Nov

PCRX

Pacira

$42.65

0.45 (1.07%)

19:24
11/21/17
11/21
19:24
11/21/17
19:24
Recommendations
Pacira analyst commentary  »

October Symphony data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 14

    Dec

  • 06

    Apr

CEIX

CONSOL Energy

, ICON

Iconix Brand

$2.55

0.28 (12.33%)

19:00
11/21/17
11/21
19:00
11/21/17
19:00
Hot Stocks
S&P announces changes to S&P SmallCap 600 index »

S&P Dow Jones Indices…

CEIX

CONSOL Energy

ICON

Iconix Brand

$2.55

0.28 (12.33%)

CNX

Consol

$16.27

0.23 (1.43%)

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

BBOX

Black Box

$4.15

0.55 (15.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIVO

TiVo

$17.65

0.15 (0.86%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

18:52
11/21/17
11/21
18:52
11/21/17
18:52
Recommendations
TiVo, Comcast analyst commentary at JPMorgan »

ITC ruling a…

TIVO

TiVo

$17.65

0.15 (0.86%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$25.35

-2.86 (-10.14%)

18:48
11/21/17
11/21
18:48
11/21/17
18:48
Recommendations
Glaukos analyst commentary at Piper Jaffray »

Glaukos selloff due to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$103.00

0.25 (0.24%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

18:31
11/21/17
11/21
18:31
11/21/17
18:31
Periodicals
Hulu sued for failure to offer audio service for blind subscribers, NY Post says »

Advocacy groups are suing…

DIS

Disney

$103.00

0.25 (0.24%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

CMCSK

Comcast

TWX

Time Warner

$89.56

1.85 (2.11%)

FOX

21st Century Fox

$30.10

0.2 (0.67%)

FOXA

21st Century Fox

$30.88

0.22 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGA

Magna

$54.29

0.37 (0.69%)

18:23
11/21/17
11/21
18:23
11/21/17
18:23
Hot Stocks
Magna announces two share repurchase programs »

Magna International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

PTLA

Portola Pharmaceuticals

$50.80

1.29 (2.61%)

18:23
11/21/17
11/21
18:23
11/21/17
18:23
Hot Stocks
Portola: FDA extends review period for PAS for Bevyxxa »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

PBMD

Prima BioMed

$1.65

-0.03 (-1.79%)

18:09
11/21/17
11/21
18:09
11/21/17
18:09
Hot Stocks
Prima BioMed secures European patent grant for lead product IMP321 in cancer »

Prima BioMed announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$36.70

0.39 (1.07%)

18:06
11/21/17
11/21
18:06
11/21/17
18:06
Earnings
Copart reports Q1 non-GAAP EPS 33c, consensus 27c »

Reports Q1 revenue 419.2M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 19

    Dec

PCTY

Paylocity

$47.79

-0.64 (-1.32%)

18:01
11/21/17
11/21
18:01
11/21/17
18:01
Hot Stocks
Paylocity chairman sells 736,845 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MDC

M.D.C. Holdings

$35.10

0.91 (2.66%)

18:01
11/21/17
11/21
18:01
11/21/17
18:01
Hot Stocks
M.D.C. Holdings declares special 8% stock dividend »

M.D.C. Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

, BBOX

Black Box

$4.15

0.55 (15.28%)

17:59
11/21/17
11/21
17:59
11/21/17
17:59
Hot Stocks
Breaking Hot Stocks news story on PDF Solutions, Black Box »

PDF Solutions to replace…

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

BBOX

Black Box

$4.15

0.55 (15.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:58
11/21/17
11/21
17:58
11/21/17
17:58
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees pressure on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CEIX

CONSOL Energy

, ICON

Iconix Brand

$2.55

0.28 (12.33%)

17:57
11/21/17
11/21
17:57
11/21/17
17:57
Hot Stocks
Breaking Hot Stocks news story on CONSOL Energy, Iconix Brand »

CONSOL Energy to replace…

CEIX

CONSOL Energy

ICON

Iconix Brand

$2.55

0.28 (12.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. says returned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TMQ

Trilogy Metals

$0.92

-0.0211 (-2.25%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Syndicate
Breaking Syndicate news story on Trilogy Metals »

Trilogy Metals files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNO

Terreno Realty

$37.74

0.74 (2.00%)

17:50
11/21/17
11/21
17:50
11/21/17
17:50
Initiation
Terreno Realty initiated at National Securities »

Terreno Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HPQ

HP Inc.

$22.47

0.355 (1.61%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Hot Stocks
HP Inc.: 'Stay tuned' for news on metal 3D printing »

Says plans to introduce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

THC

Tenet

$13.34

0.17 (1.29%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
Tenet initiated at William Blair »

Tenet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPNT

LifePoint

$43.85

0.65 (1.50%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
LifePoint initiated at William Blair »

LifePoint initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LHCG

LHC Group

$67.98

1.46 (2.19%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
LHC Group initiated at William Blair »

LHC Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

HLS

HealthSouth

$48.46

0.85 (1.79%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HealthSouth initiated at William Blair »

HealthSouth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$75.89

1.28 (1.72%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HCA Healthcare initiated at William Blair »

HCA Healthcare initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

AMED

Amedisys

$54.97

2.29 (4.35%)

17:45
11/21/17
11/21
17:45
11/21/17
17:45
Initiation
Amedisys initiated at William Blair »

Amedisys initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.